It was indeed found that Nrf2 overexpression in cancer cells decreases their sensitivity to IR and chemotherapy, while Nrf2 knockdown sensitizes the cells to such treatments (Shibata et al., 2008a; Wang et al., 2008; Solis et al., 2010; Zhang et al., 2010). The gene discussed is NFE2L2; the disease is cancer.